Thymosin Alpha-1
- Category
- Immune & Defense
- Administration routes
- Injectable
- Regulatory status
- Not FDA-approved
A synthetic 28-amino-acid peptide marketed as an immune modulator for immune support, viral infections, and cancer. Human evidence is narrow: mixed efficacy findings in chronic hepatitis B and inconclusive sepsis benefit, but longevity and immune-boosting claims are weak. It must not be used in immunosuppressed or transplant patients, and may worsen autoimmune disease. Approved abroad as thymalfasin but not FDA-approved or eligible for US compounding; unregulated products sold online are of uncertain quality.
This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer
Compiled from published research indexed through March 2026.
Overview
Thymosin Alpha-1, sold internationally as Zadaxin, is a 28-amino-acid peptide naturally produced by your thymus gland to help regulate immune function. First isolated from calf thymus extracts in 1977, the synthetic version is chemically identical to the natural form. Zadaxin is approved in over 35 countries (primarily in Asia, Latin America, and parts of Europe) for chronic hepatitis B and C and as an immune booster. It holds FDA orphan drug designations for liver cancer and melanoma but has not received full FDA approval in the United States.
How it works in the body
Activates dendritic cells and enhances their antigen presentation through toll-like receptor (TLR) signaling. It also stimulates T cell maturation in the thymus, increases natural killer cell activity, and modulates cytokine production to balance Th1/Th2 immune responses — making it both immunostimulatory and immunomodulatory.
Research overview
Thymosin Alpha-1 is one of the most extensively studied peptide therapeutics, with clinical data from over 11,000 patients across more than 30 controlled trials. It works by activating several types of immune sensors (Toll-like receptors) on dendritic cells, which then train T-cells to fight infections and tumors more effectively. It boosts both helper and killer T-cells while also dialing down the immune-suppressing PD-1 pathway that cancers exploit to hide. In hepatitis B, a meta-analysis of 353 patients found 2.67-fold higher odds of virological response 12 months after treatment, without significant differences at earlier time points. In sepsis, a meta-analysis of 11 trials (1,927 patients) found a 27% reduction in 28-day mortality, though one large recent trial found no significant benefit. It was also explored for COVID-19, with mixed results. While its hepatitis use has been largely superseded by newer antivirals, ongoing research focuses on cancer immunotherapy, sepsis, and vaccine enhancement in immunocompromised patients.
Who researches Thymosin Alpha-1?
Commonly researched by
People researching immune system support
Studied for immune modulation, antiviral, or antimicrobial properties.
Important considerations for
Those with Organ transplant recipients on immunosuppressants
HighImmune stimulation may counteract immunosuppressive therapy and trigger organ rejection.
Those with Active autoimmune flare
ModerateWhile sometimes used for autoimmune modulation, acute flares may worsen with immune stimulation.
Those who are pregnant or breastfeeding
AbsoluteNo reproductive safety data.
Safety & interactions
Do not use if
Organ transplant recipients on immunosuppressants
HighImmune stimulation may counteract immunosuppressive therapy and trigger organ rejection.
Active autoimmune flare
ModerateWhile sometimes used for autoimmune modulation, acute flares may worsen with immune stimulation.
General cautions
Pregnancy
AbsoluteNo reproductive safety data.
How to read the ratings
- Benefits
- = confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)
- Risks
- = level of concern: High · Moderate · Low · Theoretical
- Interactions
- = direction with this peptide: Protective / Synergistic · Caution · Neutral
Risk summary(6)
Rated by level of concern
Injection site discomfort/erythema (most common)
HighZadaxin (thymalfasin) prescribing information / RxList
Contraindicated in deliberately immunosuppressed patients (e.g., transplant)
HighZadaxin (thymalfasin) prescribing information / RxList
Immune stimulation could theoretically aggravate autoimmune disease
TheoreticalMechanism-based; no primary demonstration in literature
Rare allergic reactions
LowZadaxin (thymalfasin) prescribing information / RxList
Rare transient muscle atrophy, polyarthralgia with hand edema, rash
LowZadaxin (thymalfasin) prescribing information / RxList
Uncertain US regulatory status; compounded/research-grade quality
ModerateFDA interim 503A bulk drug substances policy (Category 2 listing Sept 2023; removal Sept 2024, nomination withdrawn) and PCAC review schedule
Interaction summary(5)
Rated by direction with this peptide
Interferon-alpha (incl. pegylated IFN-α)
SynergisticModerateEstablished therapeutic pairing in chronic hepatitis B/C and the best-documented interaction — Tα1 augments interferon-driven antiviral, NK, and T-cell responses.
PMID 9537454 (HCV combination RCT); PMID 2807622 (NK synergy in vivo)
Immunosuppressants / anti-rejection therapy (calcineurin inhibitors, corticosteroids, transplant regimens)
CautionModerateTα1's immunostimulatory effect may oppose intended immunosuppression; labeled contraindicated in deliberately immunosuppressed/transplant patients due to theoretical rejection or reduced efficacy of immunosuppression. Direction (Caution) and Moderate severity are appropriate — the concern is labeled but theoretical (no documented rejection cases).
Zadaxin (thymalfasin) label / RxList
Cytotoxic chemotherapy (e.g., dacarbazine, platinum-based regimens)
SynergisticLowCo-administered as an immune adjuvant with chemotherapy in cancer trials and may improve immune parameters and tolerability without added toxicity, but the pivotal randomized melanoma trial (Maio 2010, n=488) showed NO significant overall survival benefit, so synergistic anticancer efficacy is not established — the interaction is a plausible/intended adjuvant pairing, not a proven one.
PMID 20194853 (Maio 2010 melanoma RCT, negative for OS — added); PMID 11137613 (Garaci review); PMC6742685 (cancer therapy reappraisal)
Vaccines (influenza, hepatitis B)
SynergisticModerateActs as a vaccine adjuvant via TLR9 agonism, raising and sustaining seroconversion — demonstrated in small randomized hemodialysis/immunocompromised trials including prior vaccine nonresponders.
Vaccine 2012 H1N1 hemodialysis pilot (S0264410X11019372); HBV nonresponder trial
Immune checkpoint inhibitors (anti-PD-1/PD-L1)
SynergisticTheoreticalMechanistic rationale only: Tα1 lowers PD-1/Tim-3 on exhausted T cells and could complement checkpoint blockade in immuno-oncology, but this combination is proposed, not clinically demonstrated. Correctly rated Theoretical.
PMC7314217 (T-cell exhaustion reversal); immuno-oncology review S1567576923002722
Known risks(6)
Injection site reactions
LowThe most commonly reported adverse effect. Includes local discomfort, erythema, and mild pain at the subcutaneous injection site. Reported across multiple clinical trials and thousands of treated patients. Generally mild and self-limiting.
Contraindicated in immunosuppressed patients
HighBecause Ta1 enhances immune function, it is contraindicated in patients who are deliberately immunosuppressed, such as organ transplant recipients on anti-rejection medications. Use in these patients could precipitate transplant rejection or graft-versus-host disease. The Zadaxin label explicitly warns against use in transplant patients unless potential benefits clearly outweigh risks.
Potential autoimmune exacerbation
ModerateAs an immune stimulant that upregulates T-cell function, CD40/CD40-L signaling, and cytokine production, Ta1 could theoretically worsen autoimmune conditions by enhancing auto-reactive immune responses. Patients with active autoimmune diseases (lupus, rheumatoid arthritis, multiple sclerosis, etc.) should exercise caution, though paradoxically some data suggests Ta1 may promote immune tolerance in certain contexts via its effects on dendritic cell maturation.
Rare allergic reactions
LowIn rare cases, individuals may experience allergic reactions to the peptide. Symptoms can include itching, rash, or difficulty breathing. Extremely uncommon across the clinical trial database but should be monitored, particularly on first administration.
Rare musculoskeletal and dermatologic effects
LowRare reported effects include transient muscle atrophy, polyarthralgia combined with hand edema, and skin rash. These were infrequent across the 11,000+ patient clinical experience and were generally mild and reversible.
Compounded product quality concerns (US market)
ModerateGiven the uncertain US regulatory status, Ta1 from compounding pharmacies or unregulated products sold online may lack the quality controls of the pharmaceutical-grade Zadaxin product. The FDA has specifically cited concerns about immunogenicity risk with certain routes of administration and peptide impurity characterization for compounded Ta1 products. Users should ensure products are tested for purity, sterility, and endotoxin levels.
Drug interactions(7)
Immunosuppressants (cyclosporine, tacrolimus, mycophenolate, azathioprine)
Direct pharmacological antagonism. Ta1 enhances immune function (T-cell activation, dendritic cell maturation, cytokine production), which directly opposes the mechanism of immunosuppressive drugs. Combined use could reduce immunosuppressant efficacy and increase transplant rejection risk. The Zadaxin label states Ta1 should be considered contraindicated in patients who are deliberately immunosuppressed unless benefits clearly outweigh risks.
Interferon-alpha (IFN-alpha, pegylated IFN-alpha)
Documented synergistic interaction. Ta1 + IFN-alpha combination therapy has been extensively studied in hepatitis B and C with improved response rates vs. IFN alone. The combination was well tolerated with no additional adverse reactions beyond those seen with either agent alone. NK cell activity was synergistically restored in immunosuppressed models. This is a well-characterized beneficial interaction.
Corticosteroids (prednisone, dexamethasone, hydrocortisone)
Potential antagonistic interaction. Corticosteroids suppress immune function through multiple mechanisms including T-cell suppression and cytokine inhibition. Concurrent use may reduce Ta1 efficacy. High-dose corticosteroid therapy could negate Ta1's immunostimulatory effects. Dose adjustment and clinical monitoring recommended.
Cancer chemotherapy agents (dacarbazine, cisplatin, doxorubicin)
Studied in combination for cancer immunotherapy. Ta1 added to dacarbazine + IFN-alpha for melanoma did not produce additional adverse reactions. Ta1 may help restore immune function suppressed by chemotherapy. Used clinically as an adjunct to chemotherapy in HCC and NSCLC. Generally well tolerated in combination.
Antiretroviral agents (zidovudine, nucleoside analogues)
Studied in HIV combination therapy. Triple combination of Ta1 + IFN-alpha + zidovudine was well tolerated after 12 months and associated with substantial increase in CD4+ T-cell count and function (Garaci et al. 1992). No additional adverse events from the combination. Potentially beneficial synergy for immune restoration.
Checkpoint inhibitors (nivolumab, pembrolizumab, ipilimumab)
Theoretical interaction — no direct clinical data. Ta1 downregulates PD-1/PD-L1 and upregulates CD40/CD40-L, which could theoretically augment checkpoint inhibitor efficacy but also increase risk of immune-related adverse events. The combination is of significant research interest for cancer immunotherapy but should only be explored under strict medical supervision in clinical trial settings.
Other immunostimulants (IL-2, colony-stimulating factors, other peptides)
Caution advised. The Zadaxin label warns that interactions with other drugs have not been fully evaluated and that caution should be exercised when combining Ta1 with other immunomodulating drugs. Additive immune stimulation could produce excessive cytokine production or immune-mediated tissue damage.
Research & benefits
Evidence base
- Evidence Level
- Level 1-2 — Strong
- Total Studies
- 30
- Human Studies
- 30
Thymosin Alpha-1 has among the strongest clinical evidence bases of any peptide therapeutic outside of FDA-approved products. Hepatitis B results are mixed. Some trials and pooled analyses report delayed virological responses, while the 97-patient placebo-controlled phase III trial did not confirm efficacy. The sepsis evidence includes 11 RCTs with a cumulative 1,927 patients, though the largest single trial (TESTS, n=1106) was negative. The cancer immunotherapy data includes Phase II trials with FDA orphan drug designations. The COVID-19 evidence is mixed, with some studies showing immune restoration but no definitive mortality benefit. Safety data is exceptionally strong: over 11,000 treated individuals with no clinically significant adverse reactions attributable to Ta1. Animal toxicology studies showed no adverse reactions at up to 800x the clinical dose. The overall clinical picture supports Ta1 as a well-tolerated immune modulator with mixed evidence in hepatitis B and promising but inconclusive evidence in sepsis and cancer. The hepatitis indication is now largely historical given the advent of direct-acting antivirals.
Researched for(7)
Rated by confidence in the evidence
Chronic hepatitis B treatment (sustained virological response)
HighMultiple human RCTs and meta-analyses show a sustained, delayed virological response; approved in 35+ countries.
PMID 18078676 (Tα1 vs IFN meta-analysis); PMID 9581695 (RCT, Chien 1998); Cochrane review PMC8929401
Enhanced hepatitis C treatment in combination with interferon
LowHuman trials raised end-of-treatment response, but durable benefit over interferon alone was not significant.
PMID 9537454 (Sherman 1998 RCT); PMC2871658 (triple therapy in peg-IFN/RBV nonresponders); DARE meta-analysis NBK67412
Reduced mortality in sepsis (meta-analysis evidence)
MediumA 2025 pooled analysis found lower mortality, but the largest, best-designed trials were negative.
PMID 40969554 (2025 meta-analysis, Front Cell Infect Microbiol); TESTS phase 3 RCT PMID 39814420 (BMJ 2025, negative — added); ETASS trial PMC4056079
Cancer immunotherapy adjunct (melanoma, NSCLC, HCC)
LowStudied as an immune adjuvant in 40+ trials; the pivotal melanoma trial showed no survival benefit.
PMID 20194853 (Maio 2010 melanoma RCT, JCO — negative for OS, added); PMID 11137613 (Garaci review); PMC6742685 (reappraisal in cancer therapy); NCT02906150 (NSCLC maintenance trial)
Immune restoration in COVID-19 and viral infections
LowEvidence includes small randomized trials as well as conflicting cohorts; it does not establish a reliable mortality benefit.
PMC7314217 (Liu 2020, severe COVID mortality/T-cell exhaustion); PMC8102900 (propensity-matched cohort); Frontiers Immunol 2021 fimmu.2021.568789 (negative T-cell study)
Enhanced vaccine immunogenicity in immunocompromised patients
MediumSmall randomized trials in dialysis patients improved flu and hepatitis B vaccine response versus placebo.
Vaccine 2012 (Carraro, H1N1 hemodialysis pilot, S0264410X11019372); HBV nonresponder double-blind hemodialysis trial
NK cell activation synergistic with interferon
LowShown in cell studies and mice, boosting NK activity with interferon; no human trial isolates it.
PMID 2807622 (Tα1 + αβ-IFN synergy on NK in tumor-bearing mice); PMID 3851698 (modulation of NK activity by Tα1 and IFN)
Benefits(7)
Chronic hepatitis B treatment — sustained virological response
Meta-analysis by Chan et al. 2001 (J Viral Hepat, PMID 11736720) — 5 RCTs, 353 patients: OR 2.67 (95% CI 1.25-5.68) for sustained virological response at 12 months vs. placebo. Chien et al. 1998 (Hepatology, PMID 9581695) — Phase III RCT, 100 patients: complete virological response rate of 40.6% with Ta1 1.6 mg SC twice weekly. You et al. 2006 (World J Gastroenterol, PMID 17075991) randomized 62 patients to Ta1 or interferon and included 30 historical controls. Follow-up complete response was 48.3% versus 27.3%, without a significant difference between randomized groups.
Enhanced hepatitis C treatment in combination with interferon
Tuthill et al. 2010 (Ann N Y Acad Sci, PMID 20536460) — Pooled intent-to-treat analysis: sustained biochemical (ALT) response in 22.4% of patients receiving Ta1 + IFN-alpha combination therapy vs. 9.3% with IFN alone. Combination therapy also effective in IFN-non-responder populations.
Reduced mortality in sepsis (meta-analysis evidence)
2025 meta-analysis (Front Cell Infect Microbiol, PMID 40969554) — 11 RCTs, 1,927 patients: 28-day mortality significantly reduced with Ta1 (OR 0.73, 95% CI 0.59-0.90, p=0.003). Li et al. 2015 (Int J Infect Dis, PMID 25532482) — Meta-analysis of 12 trials, 1,480 patients: pooled RR 0.68 (95% CI 0.59-0.78, p<0.00001) for all-cause mortality. Note: the large TESTS trial (BMJ, PMID 39814420, n=1106) found no significant difference.
Cancer immunotherapy adjunct — melanoma, NSCLC, HCC
Garaci et al. 2012 (Expert Opin Biol Ther, PMID 22171665) — Ta1 combined with dacarbazine and IFN-alpha in metastatic melanoma. FDA orphan drug designation for stage 2b-4 malignant melanoma (2006). Preclinical models showed 32% reduction in lung metastases and 34-46% decrease in tumor growth. Studied in NSCLC and HCC as adjunct to chemotherapy.
Immune restoration in COVID-19 and viral infections
Liu et al. 2021 (Open Forum Infect Dis, PMID 33511235) — Ta1 mitigated cytokine storm in blood cells from COVID-19 patients. Shi et al. 2023 (ScienceDirect) — Ta1 restored immune homeostasis in lymphocytes during post-acute sequelae of SARS-CoV-2. Garaci et al. 1992 (Int J Clin Lab Res) — Combination of Ta1 + IFN-alpha + zidovudine in HIV increased CD4+ T-cell count and function after 12 months.
Enhanced vaccine immunogenicity in immunocompromised patients
Romani et al. 2012 (Vaccine, PMID 22178096) — Pilot study in hemodialysis patients: Ta1 enhanced immunogenicity of pandemic H1N1 influenza vaccine (Focetria) with no effect on hematology or blood chemistry. Well tolerated as vaccine adjuvant in patients with impaired immune response.
NK cell activation synergistic with interferon
Garaci et al. 1990 (Int J Immunopharmacol, PMC11038431) — Sequential treatment with Ta1 followed by IFN strongly restored NK activity in immunosuppressed mice. The synergy appeared to result from effects on NK lineage differentiation at multiple levels, with implications for combination immunotherapy protocols.
Key studies(5)
Efficacy of thymosin alpha-1 and interferon alpha in treatment of chronic viral hepatitis B: a randomized controlled study
Randomized comparison with interferon alpha, with an additional historical untreated control group62 patients24 weeks treatment + follow-upYou J, Zhuang L, Cheng HY, Yan SM, Yu L, et al.
World Journal of Gastroenterology
2006
Complete response after follow-up occurred in 14/29 Ta1 recipients (48.3%) versus 9/33 interferon recipients (27.3%); this difference was not statistically significant. Response exceeded that in the historical untreated control group.
The efficacy of thymosin in the treatment of chronic hepatitis B virus infection: a meta-analysis
Meta-analysis of randomized controlled trials5 RCTs, 353 patients total6-12 months treatment + 6-12 months post-treatment follow-upChan HL, Tang JL, Tam W, Sung JJ
Alimentary Pharmacology & Therapeutics
2001
Odds ratio for sustained virological response (HBeAg seroconversion) of Ta1 vs. placebo was 2.67 (95% CI 1.25-5.68) at 12 months post-treatment. Established the evidence base supporting international regulatory approvals.
Comprehensive Review of the Safety and Efficacy of Thymosin Alpha 1 in Human Clinical Trials
Comprehensive narrative reviewOver 11,000 human subjects across 30+ trials reviewedN/A (review spanning decades of clinical research)Dinetz E, Lee M
Alternative Therapies in Health and Medicine
2024
Systematic assessment of all major clinical trials found Ta1 to be a well-tolerated and effective immune modulator across multiple disease contexts including COVID-19, autoimmune conditions, cancer, hepatitis, HIV, and sepsis. Concluded that Ta1's safety and efficacy evidence extends well beyond the initially approved hepatitis indications. No serious adverse events attributable to Ta1 across the entire reviewed literature.
The efficacy and safety of thymosin alpha1 for sepsis (TESTS): multicentre, double blinded, randomised, placebo controlled, phase 3 trial
Phase III multicenter, double-blind, randomized, placebo-controlled trial1,106 patients with sepsis28-day primary endpointTESTS Investigators
BMJ
2025
28-day all-cause mortality was 23.4% in the Ta1 group and 24.1% in placebo (HR 0.99, 95% CI 0.77-1.27). No significant difference was found, providing no clear evidence that Ta1 decreases 28-day all-cause mortality in adults with sepsis. This large, well-powered negative trial contrasts with earlier positive meta-analyses of smaller RCTs and introduces significant uncertainty about the sepsis indication.
Thymosin alpha 1: past clinical experience and future promise
Comprehensive clinical reviewReview of all major clinical trials to dateTuthill C, Rios I, McBeath R
Annals of the New York Academy of Sciences
2010
Provided an authoritative overview of Ta1's clinical development across hepatitis B/C, cancer, HIV, and vaccine adjuvant applications. Documented the pooled hepatitis C data showing 22.4% vs. 9.3% sustained biochemical response for combination vs. IFN mono. Highlighted Ta1's exceptional safety profile across all studied populations and laid the foundation for expanded clinical investigation.
What research suggests over time
Weeks 2-4
Phase 3 RCTT-cell function and immune modulation shifts begin in immunocompromised patients.
Months 2-3
Phase 3 RCT~36% ALT normalization and 30% HBV-DNA clearance in chronic hepatitis B patients at 6 months (Wld J Gastroenterol 2006).
Long-term
International clinical useIn hepatitis B, a meta-analysis found 2.67-fold higher odds of virological response 12 months after treatment versus placebo; trial results are mixed. Approved in 35+ countries; not FDA-approved.
Regulation & availability
Why researchers look at it
Over 11,000 patients across 30+ controlled trials have shown improved immune responses with an exceptional safety record, directly addressing the progressive immune decline caused by thymus shrinkage after puberty. Interest surged during COVID-19, when it was deployed alongside standard treatments in several countries. If ongoing research continues to confirm its role in restoring age-related immune decline, it could become a cornerstone of longevity-focused immune support.
- Estimated cost
- No approved product and no verified reference price
- FDA status
- Thymosin alpha-1 is NOT FDA-approved. Orphan designations are research incentives, not marketing approvals. It is not eligible for compounding: it is not on FDA's list of bulk substances pharmacies may use. The 503A nomination was withdrawn, without restoration to Category 1, and FDA retains its compounded-product safety concerns. PCAC voted 4–17 against each form on December 4, 2024. Thymosin alpha-1 is in 503B Category 3.
- WADA status
- Thymosin alpha-1 is not named on the 2026 List. Its documented foreign therapeutic approval means FDA nonapproval alone does not trigger S0. Confirm the exact preparation with the relevant anti-doping authority.
- Prescribability
- Thymosin Alpha-1 is not FDA-approved and is not eligible for compounding: it is not on FDA's list of bulk substances pharmacies may use, and an FDA advisory committee voted against adding it in December 2024. US clinic prescribing does not establish federal bulk-compounding eligibility: the 503A nomination was withdrawn, Category 1 coverage is absent, and thymosin alpha-1 is in 503B Category 3. Internationally, thymalfasin (Zadaxin) is an approved prescription medication in over 35 countries including China, Argentina, Peru, the Philippines, Singapore, and countries across Latin America, Eastern Europe, the Middle East, and the Asia-Pacific region. Prescription thymalfasin products are authorized abroad for country-specific indications, including chronic hepatitis B, hepatitis C (combination therapy), and use as an immune adjuvant.
- Availability
- Internationally, thymalfasin (Zadaxin) is a commercially available prescription medication approved in over 35 countries, predominantly in China (where it was launched in 1996 and accounted for ~92% of worldwide sales by 2007), Argentina, Peru, the Philippines, Singapore, and countries across Latin America, Eastern Europe, the Middle East, and Asia-Pacific. In China, Zadaxin was marketed by SciClone Pharmaceuticals and was widely used in clinical settings for hepatitis B and as an immune adjuvant. Prescription thymalfasin is available in countries with relevant authorizations and can be obtained from pharmacies where Zadaxin is approved. In the United States, Ta1 is NOT available as an FDA-approved pharmaceutical. Some US clinics advertise compounded Ta1, but those listings do not establish federal eligibility. No qualifying US bulk-compounding pathway was identified under 503A or 503B; FDA's December 2024 PCAC briefing proposed against inclusion on the 503A Bulks List. Ta1 has active registrations on ClinicalTrials.gov (e.g., NCT04487444, NCT06821100); clinical-trial access depends on each study's current recruitment and eligibility requirements. No legitimate over-the-counter pathway exists in the US or EU.
International status
EU
Not EMA-approved; approved in individual countries
US
Thymosin Alpha-1 is not FDA-approved and is not eligible for compounding: it is not on FDA's list of bulk substances pharmacies may use, and an FDA advisory committee voted against adding it in December 2024.
China
Approved (Zadaxin) — widely used for hepatitis B and as cancer adjunct
India
Approved for hepatitis B
Italy
Approved as an adjuvant to influenza vaccination in immunocompromised individuals.
Regulatory timeline(16)
- 1966Abraham White and Allan Goldstein at Albert Einstein College of Medicine first name thymic-derived immunomodulatory factors 'Thymosins' in a PNAS publication. Beginning of the thymosin research program.
- 1972Goldstein team moves to University of Texas Medical Branch (UTMB) Galveston. Preparation of Thymosin Fraction 5 (TF5), a highly active partially purified calf thymus extract containing multiple peptides.
- 1977Thymosin Alpha-1 isolated and characterized from Thymosin Fraction 5 by Goldstein and colleagues. Published as a 28-amino-acid immunologically active thymic polypeptide (PMID 265536). US Patent 4,079,127 filed.
- 1985-1990sEarly Phase I/II clinical trials begin for chronic hepatitis B. Alpha-1 Biomedical Inc. founded to develop synthetic thymalfasin. First international regulatory filings submitted.
- 1996Zadaxin (thymalfasin) launched in China for treatment of chronic hepatitis B by SciClone Pharmaceuticals. This becomes the primary commercial market, eventually representing 92% of worldwide Zadaxin sales.
- 1998Chien et al. publish Phase III RCT results in Hepatology showing 40.6% complete virological response rate in chronic HBV (PMID 9581695). Pivotal trial supporting international approvals.
- 1999-2000Andreone et al. publish Phase III multicenter, double-blind, placebo-controlled study of 97 HBV patients (PMID 10607256). Regulatory approvals expand to Argentina, Peru, Philippines, Singapore, and additional countries.
- 2001Chan et al. publish meta-analysis in Alimentary Pharmacology & Therapeutics confirming efficacy across 5 RCTs with OR 2.67 for virological response vs. placebo (PMID 11736720). Ta1 approved in 35+ countries total.
- 2006FDA grants orphan drug designation for thymalfasin injection (Zadaxin) for treatment of stage 2b through stage 4 malignant melanoma (March 2006). Additional orphan drug designations for hepatocellular carcinoma, DiGeorge syndrome, and chronic hepatitis B.
- 2010Tuthill et al. publish comprehensive clinical review in Annals of the New York Academy of Sciences (PMID 20536460), summarizing decades of clinical experience and establishing Ta1's safety profile across 11,000+ patients.
- 2020-2021Multiple clinical investigations of Ta1 for COVID-19 initiated. ClinicalTrials.gov registrations include NCT04487444. Studies show immune restoration effects in severe COVID-19 patients, generating renewed global interest in Ta1.
- 2023-2024FDA places Ta1 on Category 2 restricted list during peptide enforcement actions, blocking US compounding pharmacy access. The 503A nomination was withdrawn. Removal from Category 2 did not place Ta1 in Category 1; FDA subsequently evaluated the free base and acetate on its own initiative.
- December 2024FDA Pharmacy Compounding Advisory Committee (PCAC) meeting: FDA briefing document proposes that thymosin alpha-1 (free base) and thymosin alpha-1 acetate NOT be included on the 503A Bulks List, citing immunogenicity and characterization concerns. Final determination pending.
- January 2025TESTS trial results published in BMJ — largest sepsis RCT (n=1106) finds no significant mortality benefit with Ta1 (HR 0.99, 95% CI 0.77-1.27), introducing uncertainty about the sepsis indication (PMID 39814420).
- 2024Dinetz & Lee publish comprehensive review of safety and efficacy across 11,000+ patients in 30+ trials (PMID 38308608). Garaci et al. publish phenotypic drug discovery perspective arguing for expanded Ta1 applications.
- 2026-presentTa1 remains approved in 35+ countries internationally. PCAC completed its review in December 2024 and voted against both forms. The withdrawn 503A nomination has not produced Category 1 coverage or positive-list inclusion; thymosin alpha-1 remains in 503B Category 3. Active clinical trials continue (NCT06821100). No FDA marketing approval.
Sources & FAQs
Research sources(24)
- Goldstein et al. 1977 — Original isolation and characterization of thymosin alpha 1
- Goldstein 2007 — Thymosin alpha1: a historical overview
- Goldstein 2007 — History of the discovery of the thymosins
- Tuthill et al. 2010 — Past clinical experience and future promise (Ann N Y Acad Sci)
- Chan et al. 2001 — Meta-analysis: efficacy of thymosin in chronic HBV infection
- Naylor 1999 — Zadaxin (thymosin alpha1) for the treatment of viral hepatitis (review)
- Chien et al. 1998 — Phase III RCT, chronic hepatitis B
- Andreone et al. 2000 — Phase III multicenter placebo-controlled HBV study
- Dinetz & Lee 2024 — Comprehensive review of safety and efficacy in human clinical trials
- Romani et al. 2012 — Ta1 enhances H1N1 vaccine immunogenicity in hemodialysis patients
- Li et al. 2015 — Sepsis meta-analysis (Int J Infect Dis)
- TESTS Investigators 2025 — Phase III sepsis RCT (BMJ, n=1106)
- 2025 — Sepsis meta-analysis of 11 RCTs (Front Cell Infect Microbiol)
- Liu et al. 2021 — Ta1 mitigates cytokine storm in COVID-19 (Open Forum Infect Dis)
- Garaci et al. 2024 — Phenotypic drug discovery: a case for thymosin alpha-1 (Frontiers)
- Costantini et al. 2019 — Thymosin alpha 1 comprehensive literature review (PMC)
- Huang et al. 2023 — Thymosin alpha-1 and its role in viral infectious diseases (Molecules MDPI)
- DrugBank — Thymalfasin drug profile (DB04900)
- RxList — Zadaxin prescribing information
- ClinicalTrials.gov — Thymalfasin COVID-19 trial (NCT04487444)
- ClinicalTrials.gov — Thymalfasin vaccine enhancer trial (NCT06821100)
- FDA PCAC December 2024 meeting — Ta1 compounding review materials
- WADA 2026 Prohibited List
- FDA orphan drug designation search — thymalfasin
Frequently asked questions(5)
What is the difference between Thymosin Alpha-1 and Thymosin Beta-4 (TB-500)?
Despite sharing the 'thymosin' name, these are completely different peptides with distinct structures, mechanisms, and applications. Thymosin Alpha-1 (Ta1) is a 28-amino-acid immune-modulating peptide that acts through Toll-like receptors to enhance T-cell and dendritic cell function. Thymosin Beta-4 (Tb4) is a 43-amino-acid peptide primarily involved in actin sequestration, tissue repair, wound healing, and angiogenesis. They were both originally isolated from thymus extract (Thymosin Fraction 5) but have entirely different amino acid sequences and biological roles. Importantly, Tb4 and its fragment TB-500 are on the WADA Prohibited List under growth factors (S2), while Ta1 is not specifically listed. Ta1 has regulatory approval in 35+ countries; Tb4/TB-500 has none.
Why is Thymosin Alpha-1 approved in 35+ countries but not in the US?
This reflects differing regulatory standards and commercial strategy. The FDA requires large, well-powered Phase III trials meeting specific statistical endpoints for approval, and SciClone Pharmaceuticals focused its commercial efforts on China and other markets where regulatory pathways were more accessible. By 2007, 92% of Zadaxin worldwide sales were in China. The FDA did grant four orphan drug designations, but the company never completed the US-specific Phase III program needed for NDA approval. The development of direct-acting antivirals for hepatitis (the primary approved indication) further reduced the commercial incentive for US registration. The peptide's lack of US approval reflects commercial decisions and regulatory pathway requirements rather than safety or efficacy concerns — the safety record across 11,000+ patients is exceptional.
Is Thymosin Alpha-1 safe? What are the side effects?
Ta1 has an exceptionally well-documented safety profile. During clinical experience involving over 11,000 individuals across all age groups, no clinically significant adverse reactions attributable to Ta1 were reported. Adverse experiences have been infrequent and mild, consisting primarily of local discomfort at the injection site and rare instances of erythema, transient muscle atrophy, polyarthralgia with hand edema, and rash. Animal toxicology studies showed no adverse reactions at single doses hundreds of times the clinical dose or with repeated dosing for 13 weeks. Ta1 should not be used in patients who are deliberately immunosuppressed (e.g., organ transplant recipients) as it enhances immune function.
Can Thymosin Alpha-1 help with COVID-19 or Long COVID?
Several studies investigated Ta1 during the COVID-19 pandemic with mixed results. Positive findings include: reversal of T-cell exhaustion, recovery of immune function, increased CD4+ T-cell counts in lymphocytopenic patients, attenuation of acute lung injury, and mitigation of cytokine storm in blood cells from COVID-19 patients. A single-cell RNA sequencing study showed Ta1 favorably modulated the immune landscape of COVID-19 patients. For Long COVID (PASC), a 2023 study demonstrated Ta1 restored immune homeostasis in lymphocytes. However, a multicenter retrospective study found no association between Ta1 use and decreased mortality in severe COVID-19. The evidence supports immune restoration effects but not a clear mortality benefit.
Is Thymosin Alpha-1 still useful for hepatitis now that direct-acting antivirals exist?
For hepatitis C, direct-acting antivirals (DAAs) like sofosbuvir achieve cure rates exceeding 95%, making Ta1 combination therapy obsolete for HCV. For hepatitis B, nucleos(t)ide analogues (entecavir, tenofovir) are now standard of care and far more effective than Ta1 monotherapy. However, Ta1 may still have a niche role as an immune adjuvant in HBV patients who are poor responders to standard antiviral therapy, or in resource-limited settings where access to modern antivirals is restricted. The hepatitis indication is now primarily of historical significance for Ta1's clinical development, though the data from those trials established the safety and immune-modulating profile that supports investigation in other indications like cancer and sepsis.